CNTA

Centessa Pharmaceuticals PLC

Add to Watchlist

Advanced Chart

12.040

-0.420(-3.370%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

12.325

Open

12.160

VWAP

12.16

Vol

176.66K

Mkt Cap

1.66B

Low

11.970

Amount

2.15M

EV/EBITDA(TTM)

Total Shares

113.04M

1.38B

EV/OCF(TTM)

P/S(TTM)

Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company's advanced product candidate, SerpinPC, is a subcutaneously administered inhibitor of activated protein C (APC) being developed as a potential treatment for hemophilia. Leveraging its LockBody technology, it is developing an approach to selectively drive potent effector function activity, such as CD47 or CD3, into the tumor microenvironment (TME) while avoiding systemic toxicity. Its first LockBody product candidate, LB101, is a conditionally tetravalent PD-L1xCD47 bispecific monoclonal antibody used in solid tumors. Its other programs consist of earlier-stage preclinical assets, including ORX750, an orally administered, selective Orexin Receptor-2 (OX2R) agonist for the treatment of narcolepsy (NT1) with potential expansion into other sleep disorders, and MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

-0.325

-12.16%

-0.315

-21.25%

-0.280

-26.32%

Estimates Revision

Stock Price

Go Down

-29.47%

In Past 3 Month

6 Analyst Rating

163.70% Upside

Wall Street analysts forecast CNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNTA is 31.75 USD with a low forecast of 27.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

163.70% Upside

Current: 12.040

Low

27.00

Averages

31.75

High

38.00

163.70% Upside

Current: 12.040

Low

27.00

Averages

31.75

High

38.00

Chardan Capital

Rudy Li

Strong Buy

Initiates

$30

2025-05-08

Reason

Chardan Capital

Rudy Li

Price Target

$30

2025-05-08

Initiates

Strong Buy

Reason

Piper Sandler

Biren Amin

Buy

Initiates

$38

2025-03-31

Reason

Piper Sandler

Biren Amin

Price Target

$38

2025-03-31

Initiates

Buy

Reason

Piper Sandler analyst Biren Amin initiated coverage of Centessa with an Overweight rating and $38 price target. The company is developing a multi-asset orexin receptor 2 agonist franchise to address excessive daytime sleepiness, fatigue, impaired attention, and cognitive defects across neurodegenerative and neuropsychiatric disorders, the analyst tells investors in a research note. The firm believes orexin agonists "have wide reaching potential." Centessa's ORX750 is a potential best-in-class OX2R Agonist and the upcoming Phase 2a data in 2025 "represents a major catalyst," contends Piper.

Guggenheim

Debjit Chattopadhyay

Strong Buy

Reiterates

$28

2025-03-26

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

$28

2025-03-26

Reiterates

Strong Buy

Reason

Morgan Stanley

Jeffrey Hung

Buy

Initiates

$27

2025-03-07

Reason

Morgan Stanley

Jeffrey Hung

Price Target

$27

2025-03-07

Initiates

Buy

Reason

Morgan Stanley assumed coverage of Centessa with an Overweight rating and $27 price target. The market potential for orexin 2 agonists, including ORX750, is "likely under-appreciated," says the analyst, who models greater than $5B in unadjusted revenues for ORX750 across hypersomnias, which is "meaningfully above" consensus estimates of about $3B.

Guggenheim

Debjit Chattopadhyay

Strong Buy

Reiterates

n/a

2025-02-10

Reason

Guggenheim

Debjit Chattopadhyay

Price Target

n/a

2025-02-10

Reiterates

Strong Buy

Reason

TD Cowen

Stacy Ku

Strong Buy

Initiates

n/a

2025-01-07

Reason

TD Cowen

Stacy Ku

Price Target

n/a

2025-01-07

Initiates

Strong Buy

Reason

TD Cowen initiated coverage of Centessa with a Buy rating and no price target. The firm says the company's ORX750 has a "best in class profile as a transformative therapy" in excessive daytime sleepiness. Key opinion leaders highlight the significant unmet need that should support multiple competitive entrants and given ORX750's potency and safety, TD expects clinical differentiation and commercial success in narcolepsy and other hypersomnia indications, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Centessa Pharmaceuticals PLC (CNTA.O) is -8.70, compared to its 5-year average forward P/E of -5.23. For a more detailed relative valuation and DCF analysis to assess Centessa Pharmaceuticals PLC 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.23

Current PE

-8.70

Overvalued PE

-2.33

Undervalued PE

-8.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.70

Current EV/EBITDA

-6.24

Overvalued EV/EBITDA

-0.18

Undervalued EV/EBITDA

-7.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

8.19

Current PS

982.90

Overvalued PS

99.21

Undervalued PS

-82.82